StreetInsider.com News Articles

Form 10-Q Prelude Therapeutics For: Jun 30

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901915.html

Form 10-Q Prelude Therapeutics For: Jun 30

Tue, 11 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260811/26901915.html

Form 8-K Prelude Therapeutics For: Aug 11

Tue, 11 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26901753.html

Form 8-K Prelude Therapeutics For: Aug 11

Tue, 11 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260811/26901753.html

Prelude Therapeutics Incorporated (PRLD) Tops Q2 EPS by 9c

Tue, 11 Aug 2026 07:18:33 -0400

Prelude Therapeutics Incorporated (NASDAQ: PRLD) reported Q2 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.71 million.

For earnings history and earnings-related data on Prelude Therapeutics Incorporated (PRLD) click here.

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

Current cash runway expected into the second quarter of 2028 with $155 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Tue, 11 Aug 2026 07:00:00 -0400

The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter

Presented preclinical data demonstrating differentiated profile of PRT13722, at the American Association for Cancer Research (AACR) Annual Meeting 2026

Enrollment continues in Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF)

Current cash runway expected into the second quarter of 2028 with $155 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2026

H.C. Wainwright Reiterates Buy Rating on Prelude Therapeutics (PRLD)

Wed, 29 Jul 2026 06:53:58 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $8.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented: "Yesterday, Incyte announced that it has discontinued further development of INCB160058 (a JAK2V617F inhibitor) following a comprehensive review of available data and shall prioritize its next-generation JAK2V617F-targeted pipeline, with preclinical data expected for its next-generation JAK2V617F-targeted inhibitor in 2H26. We believe this announcement has positive read-through for Prelude given Incyte's exclusive option agreement, inked in November 2025, to acquire PRT12396, Prelude's JAK2V617F-selective JH2 inhibitor currently in Phase 1 development for polycythemia vera (PV) and myelofibrosis (MF). Should Incyte exercise its

H.C. Wainwright Reiterates Buy Rating on Prelude Therapeutics (PRLD)

Wed, 15 Jul 2026 07:39:13 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $8.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented: ' Earlier this month, CSPC Pharmaceutical (HKG: 1093; not rated) announced that it has initiated a Phase 1 trial in China (NCT07692776) evaluating SYH-2095 (a KAT6A/B inhibitor) for the treatment of advanced malignant tumors as a monotherapy or in combination regimens. With SYH-2095 entering clinical testing, the number of KAT6 inhibitors currently in development has increased to 12. Although competition within the KAT6 inhibitor landscape is growing, we highlight the encouraging preclinical data that Prelude presented at AACR 2026 for

Form SCHEDULE 13G Prelude Therapeutics Filed by: Soleus Private Equity Fund III, L.P.

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748383.html

Form SCHEDULE 13G Prelude Therapeutics Filed by: Soleus Private Equity Fund III, L.P.

Wed, 08 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260708/26748383.html

Prelude Therapeutics (PRLD) Reiterated at Market Outperform by Citizens

Wed, 01 Jul 2026 04:53:20 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 price target on Prelude Therapeutics (NASDAQ: PRLD).

The analyst commented, "File IND for KAT6A degrader PRT13722 and initiate Phase 1 study. Prelude’s second clinical program since its strategic reset is PRT13722, a highly selective KAT6A degrader for ER+/HER2− breast cancer. AACR 2026 preclinical data showed picomolar KAT6A degradation with high selectivity over KAT6B and other MYST proteins, deeper and more complete tumor regressions than Pfizer’s KAT6A/B inhibitor prifetrastat in head-to-head ER+/HER2− CDX and PDX models, and 100% (8/8) durable complete responses in a posttamoxifen PDX model. As importantly, PRT13722 showed

Form 4 Prelude Therapeutics For: Jun 09 Filed by: 667, L.P.

Wed, 10 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26630550.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: 667, L.P.

Wed, 10 Jun 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26630550.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Babler Martin

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630077.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Babler Martin

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630077.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Dorton Katina

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630103.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Dorton Katina

Wed, 10 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260610/26630103.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Bonita David P

Wed, 10 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260610/26630037.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Bonita David P

Wed, 10 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260610/26630037.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Sandor Victor

Wed, 10 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260610/26630019.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: Sandor Victor

Wed, 10 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260610/26630019.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: FRIEDMAN PAUL A

Wed, 10 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260610/26630013.html

Form 4 Prelude Therapeutics For: Jun 09 Filed by: FRIEDMAN PAUL A

Wed, 10 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260610/26630013.html

Form 8-K Prelude Therapeutics For: Jun 09

Wed, 10 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260610/26629990.html